Radioactive antibody could boost stem cell transplant success in tough leukemia
NCT ID NCT07157514
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a radioactive antibody (131I-apamistamab) along with chemotherapy and low-dose radiation to prepare the body. The goal is to see if this combination helps patients live longer and achieve remission. The trial has two parts: first finding the best dose, then comparing it to standard care in about 306 adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
131I-apamistamab (a radioactive antibody targeting cancer cells)
What this could lead to
If successful, this could offer a more effective transplant preparation for people with hard-to-treat AML, potentially improving survival and remission rates.
What could go wrong
This is an early-to-mid-stage trial, so the benefits are not proven. The treatment involves radiation and strong chemotherapy, which carry risks like severe side effects or transplant complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••